💥 Gate Square Event: #PostToWinCGN 💥
Post original content on Gate Square related to CGN, Launchpool, or CandyDrop, and get a chance to share 1,333 CGN rewards!
📅 Event Period: Oct 24, 2025, 10:00 – Nov 4, 2025, 16:00 UTC
📌 Related Campaigns:
Launchpool 👉 https://www.gate.com/announcements/article/47771
CandyDrop 👉 https://www.gate.com/announcements/article/47763
📌 How to Participate:
1️⃣ Post original content related to CGN or one of the above campaigns (Launchpool / CandyDrop).
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinCGN
4️⃣ Include a screenshot s
Novo Nordisk plans to acquire Metsera for $9 billion, challenging Pfizer's established deal.
Jin10 data reported on October 31 that Danish pharmaceutical company Novo Nordisk (NVO.N) launched a proactive acquisition of obesity drug developer Metsera on Thursday, with an offer of up to $9 billion, aiming to surpass the $7.3 billion deal reached by Pfizer (PFE.N) last month, which may trigger legal actions against the biotech company. The company proposed to acquire Metsera for $56.50 per share in cash, with an additional payment of $21.25 per share upon achieving specific milestones. Metsera stated in a separate announcement that Novo Nordisk's new offer is superior to the Pfizer proposal. According to the protocol, Pfizer currently has four days to modify the original proposal, and if Metsera ultimately determines the new offer is better, it has the right to terminate the agreement with Pfizer. Following the announcement, Metsera's stock price surged over 20%, with a cumulative rise of 78% over the past three months, while Novo Nordisk's stock price in Copenhagen fell nearly 4%.